close

Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer. The company's lead product includes CK-1827452, a cardiac muscle myosin activator, which is in Phase IIa clinical trials for the treatment of heart failure. Its products under development stage comprise Ispinesib, a kinesin spindle protein inhibitor that is in Phase I/II clinical trials for the treatment of metastatic breast cancer; SB-743921, which is in Phase I/II trials to treat patients with non-Hodgkin or Hodgkin lymphoma; and GSK-923295, centromere-associated protein E inhibitor, which is in Phase I clinical trials to treat patients with refractory solid tumors. The company's products under preclinical stage consist of CK-2017357, a skeletal sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting; and smooth muscle myosin inhibitor for the treatment of pulmonary arterial hypertension, and diseases and medical conditions associated with bronchoconstriction. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure, as well as with GlaxoSmithKline to develop GSK-923295. The company was founded in 1997 and is headquartered in South San Francisco, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.20
Volume	294751
Volume Avg	248628
52 Week High	1.69
52 Week Low	0.89
PE	N/A
PE (group average)	39
EPS Year	-0.72
EPS change Q/Q	-5.88%
EPS change Q/Q Yr ago	-10%
EPS change Q/Q next Q est	-63.64%
EPS change Y/Y	-1000%
REV change Q/Q	-27.27%
REV change Q/Q Yr ago	33.33%
EPS next Q est	-0.11
EPS next Y est	-0.14
Divident Annual	0.00
Dividend Yield	0%